Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Melanoma Res

Retrieve available abstracts of 221 articles:
HTML format
Text format



Single Articles


    April 2017
  1. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
    Does pregnancy influence melanoma prognosis? A meta-analysis.
    Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
    PubMed     Text format     Abstract available


  2. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
    Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
    Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
    PubMed     Text format     Abstract available


  3. PISCIOLI F, Pusiol T, Roncati L
    Critical points of T1 stage in primary melanoma.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
    PubMed     Text format    


  4. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
    Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
    PubMed     Text format     Abstract available


  5. THOMSON CH, Cassell O, Peach H, Holloway S, et al
    Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
    Melanoma Res. 2017;27:121-125.
    PubMed     Text format     Abstract available


  6. ROGIERS A, Wolter P, Bechter O
    Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
    Melanoma Res. 2017;27:164-167.
    PubMed     Text format     Abstract available


    March 2017
  7. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
    beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
    Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
    PubMed     Text format     Abstract available


  8. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
    Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
    PubMed     Text format     Abstract available


  9. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
    Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
    PubMed     Text format     Abstract available


  10. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
    Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
    PubMed     Text format     Abstract available


  11. FALLENI M, Savi F, Tosi D, Agape E, et al
    M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
    Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
    PubMed     Text format     Abstract available


  12. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
    Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
    Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
    PubMed     Text format     Abstract available


  13. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
    Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
    Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
    PubMed     Text format     Abstract available


  14. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
    Clinical and dermoscopic features of truly amelanotic plantar melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
    PubMed     Text format     Abstract available


  15. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
    Interactions from complementary and alternative medicine in patients with melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
    PubMed     Text format     Abstract available


    February 2017
  16. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
    BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
    Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
    PubMed     Text format     Abstract available


  17. TAS F, Erturk K
    Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
    PubMed     Text format     Abstract available


  18. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
    Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
    PubMed     Text format     Abstract available


  19. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
    A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
    Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
    PubMed     Text format     Abstract available


  20. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
    PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
    PubMed     Text format     Abstract available


  21. LI FJ, Li LM, Zhang RH, Xu C, et al
    The role of 5-hydroxymethylcytosine in melanoma.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
    PubMed     Text format     Abstract available


  22. TESIO V, Ribero S, Castelli L, Bassino S, et al
    Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
    Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
    PubMed     Text format     Abstract available


  23. RIBERO S, Longo C, Specchio F, Piana S, et al
    Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
    Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
    PubMed     Text format     Abstract available


    January 2017
  24. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
    Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
    Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
    PubMed     Text format     Abstract available


  25. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
    Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
    PubMed     Text format     Abstract available


  26. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
    The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
    PubMed     Text format     Abstract available


  27. OBEID JM, Hu Y, Erdag G, Leick KM, et al
    The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
    PubMed     Text format     Abstract available


  28. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
    Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
    PubMed     Text format     Abstract available


  29. LADWA R, Atkinson V
    The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
    PubMed     Text format     Abstract available


  30. TAS F, Erturk K
    Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
    PubMed     Text format     Abstract available


  31. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
    Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
    PubMed     Text format     Abstract available


  32. LV C, Dai H, Sun M, Zhao H, et al
    Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
    Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
    PubMed     Text format     Abstract available


  33. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
    Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
    PubMed     Text format     Abstract available


    December 2016
  34. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
    Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
    Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
    PubMed     Text format     Abstract available


  35. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
    Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
    Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
    PubMed     Text format     Abstract available


  36. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
    New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  37. MININI R, Rohrmann S, Braun R, Korol D, et al
    Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  38. PISCIOLI F, Pusiol T, Roncati L
    Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
    Melanoma Res. 2016;26:636.
    PubMed     Text format    


  39. PISCIOLI F, Pusiol T, Roncati L
    Histopathological determination of thin melanomas at risk for metastasis.
    Melanoma Res. 2016;26:635.
    PubMed     Text format    


    November 2016
  40. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
    Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    October 2016
  41. PAOLINO G, Panetta C, Cota C, Didona D, et al
    Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  42. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
    Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  43. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
    Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  44. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
    Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  45. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
    High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  46. LIM MS, Wang JH, Power DG, Redmond HP, et al
    Inflammatory regulation of stem-like cells in melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  47. ADAMS G, Foote M, Brown S, Burmeister B, et al
    Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  48. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
    Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  49. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
    A case report of bullous pemphigoid associated with a melanoma and review of the literature.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  50. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
    Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  51. HOAG JR, Hegde U, Zweifler R, Berwick M, et al
    Competing risks survival of older patients with metastatic cutaneous melanoma: a SEER population-based study.
    Melanoma Res. 2016;26:505-512.
    PubMed     Text format     Abstract available


    September 2016
  52. KUBECEK O, Kopecky J
    Microsatellite instability in melanoma: a comprehensive review.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  53. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
    Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  54. FAILING JJ, Finnes HD, Kottschade LA, Allred JB, et al
    Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  55. KARABULUT YY, Erdogan S, Sayar H, Ergen A, et al
    Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  56. ROMAINE ST, Wells-Jordan P, de Haro T, Dave-Thakrar A, et al
    A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    August 2016
  57. DANISH HH, Patel KR, Switchenko JM, Gillespie TW, et al
    The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  58. ZOROQUIAIN P, Mayo-Goldberg E, Alghamdi S, Alhumaid S, et al
    Melanocytoma-like melanoma may be the missing link between benign and malignant uveal melanocytic lesions in humans and dogs: a comparative study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  59. MCQUADE JL, Posada LP, Lecagoonporn S, Cain S, et al
    A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  60. FORTES C, Mastroeni S, Botta G, Boffetta P, et al
    Glutathione S-transferase M1 null genotype, household pesticides exposure and cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  61. SADHU SS, Wang S, Averineni RK, Seefeldt T, et al
    In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  62. DETRIXHE A, Libon F, Mansuy M, Nikkels-Tassoudji N, et al
    Melanoma masquerading as nonmelanocytic lesions.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  63. DE LEEDE EM, Burgmans MC, Kapiteijn E, Luyten GP, et al
    Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  64. BRUNET-POSSENTI F, Mignot S, Deschamps L, Descamps V, et al
    Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    July 2016
  65. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Complete response to high-dose IL-2 and enhanced IFNgamma+Th17 : TREG ratio in a melanoma patient.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  66. ENNINGA EA, Nevala WK, Holtan SG, Leontovich AA, et al
    Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  67. FRANK GA, Aleksakhina SN, Zavalishina LE, Kekeyeva TV, et al
    BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  68. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
    Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  69. OLSEN CM, Hyrich KL, Knight LL, Green AC, et al
    Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  70. MAYER JE, Swetter SM, Miller DR, Sober AJ, et al
    Association of nevus count with prevention attitudes and behaviors before melanoma diagnosis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  71. TAS F, Erturk K
    Presence of histological regression as a prognostic factor in cutaneous melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    June 2016
  72. FEDORENKO IV, Evernden B, Kenchappa RS, Sahebjam S, et al
    A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  73. HERMS F, Kramkimel N, Regnier-Rosencher E, Carlotti A, et al
    Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  74. WEN X, Wang Y, Ding Y, Li D, et al
    Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
    Melanoma Res. 2016;26:284-9.
    PubMed     Text format     Abstract available


  75. MEHTA A, Gupta A, Hannallah F, Koshy T, et al
    Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
    Melanoma Res. 2016;26:319-20.
    PubMed     Text format    


    May 2016
  76. LUTTMANN N, Gratz V, Haase O, Eckey T, et al
    Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  77. YANG S, Leone D, Frydenlund N, Hoang M, et al
    Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  78. VAN DER PLOEG IM, Madu MF, van der Hage JA, Wouters MW, et al
    Blue dye can be safely omitted in most sentinel node procedures for melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  79. KUK SK, Won CH, Lee WJ, Shin WJ, et al
    Prognostic significance of nestin in primary malignant melanoma of the oral cavity.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  80. HUGEL R, Muendlein A, Volbeding L, Drexel H, et al
    Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  81. ROGERS Z, Elliott F, Kasparian NA, Bishop DT, et al
    Psychosocial, clinical and demographic features related to worry in patients with melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  82. ESCOBAR GF, Arraes JA, Bakos L, Ashton-Prolla P, et al
    Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  83. LEE SF, Atkinson V
    A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    April 2016
  84. KROGH M, Christensen I, Bouwhuis M, Johansen JS, et al
    Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  85. ROMMENS K, Jegou D, De Backer H, Weyler J, et al
    Seasonal variation in cutaneous melanoma incidence, link with recent UV levels: a population-based study in Belgium (2006-2011).
    Melanoma Res. 2016;26:195-201.
    PubMed     Text format     Abstract available


  86. NGUYEN J, Bernert R, In K, Kang P, et al
    Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.
    Melanoma Res. 2016;26:125-37.
    PubMed     Text format     Abstract available


  87. PAOLINO G, Moliterni E, Lopez T, Cardone M, et al
    Serum tryptase levels in melanoma patients: first results of clinicopathological features.
    Melanoma Res. 2016;26:207-8.
    PubMed     Text format    


  88. VULTUR A, Schanstra T, Herlyn M
    The promise of 3D skin and melanoma cell bioprinting.
    Melanoma Res. 2016;26:205-6.
    PubMed     Text format    


  89. CHENG C, Yang HW, Shang JF, Li WW, et al
    Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
    Melanoma Res. 2016;26:117-24.
    PubMed     Text format     Abstract available


  90. WANG LE, Li C, Xiong P, Gershenwald JE, et al
    4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
    Melanoma Res. 2016;26:181-7.
    PubMed     Text format     Abstract available


    March 2016
  91. SKINNER CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, et al
    Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  92. HWANG SJ, Carlos G, Wakade D, Sharma R, et al
    Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  93. JOSEPH RW, Cappel M, Tzou K, Bagaria S, et al
    Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  94. PADDOCK LE, Lu SE, Bandera EV, Rhoads GG, et al
    Skin self-examination and long-term melanoma survival.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  95. BAROUDJIAN B, Lourenco N, Pages C, Chami I, et al
    Anti-PD1-induced collagenous colitis in a melanoma patient.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  96. QASSEMYAR A, Gabert PE, Kluza J, Duquennoy-Martinot V, et al
    Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  97. FLOUDAS CS, Chandra AB, Xu Y
    Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  98. LIN RL, Wang TJ, Joyce CJ, Mihm MC Jr, et al
    Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  99. WHIPPLE CA, Boni A, Fisher JL, Hampton TH, et al
    The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  100. JIANG H, Xu W, Zhang F, Wei L, et al
    Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  101. ESPINOSA E, Soriano V, Malvehy J, Berrocal A, et al
    Treatment patterns of adjuvant interferon-alpha2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    February 2016
  102. PATEL BG, Ahmed KA, Johnstone PA, Yu HM, et al
    Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  103. SINGH P, Kim HJ, Schwartz RA
    Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  104. TAS F, Bilgin E, Erturk K, Duranyildiz D, et al
    Clinical significance of serum claudin-1 levels in melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  105. VOIT CA, Oude Ophuis CM, Ulrich J, van Akkooi AC, et al
    Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  106. MORIARTY WF, Kim E, Gerber SA, Hammers H, et al
    Neuropilin-2 promotes melanoma growth and progression in vivo.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  107. KOTTSCHADE LA, McWilliams RR, Markovic SN, Block MS, et al
    The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  108. IMREDI E, Toth B, Doma V, Barbai T, et al
    Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  109. KILIAN MM, Herwig MC, Holz FG, Tuting T, et al
    Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma.
    Melanoma Res. 2016;26:89-91.
    PubMed     Text format    


  110. SLOOT S, Zager JS, Kudchadkar RR, Messina JL, et al
    BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Melanoma Res. 2016;26:83-7.
    PubMed     Text format     Abstract available


  111. SALDANHA G, Potter L, Lee YS, Watson S, et al
    MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.
    Melanoma Res. 2016;26:21-8.
    PubMed     Text format     Abstract available


  112. PISCIOLI F, Pusiol T, Roncati L
    Diagnostic approach to melanocytic lesion of unknown malignant potential.
    Melanoma Res. 2016;26:91-2.
    PubMed     Text format    


    January 2016
  113. TODO Y, Okamoto K, Suzuki Y, Minobe S, et al
    Radicality of initial surgery for primary malignant melanoma of the vagina.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  114. CHIRIBOGA L, Meehan S, Osman I, Glick M, et al
    Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  115. KONG BY, Micklethwaite KP, Swaminathan S, Kefford RF, et al
    Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  116. SHOUSHTARI AN, Ong LT, Schoder H, Singh-Kandah S, et al
    A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  117. GLAZER ES, Bartels PH, Lian F, Kha ST, et al
    Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  118. MUSTAPHA N, Mokdad-Bzeouich I, Maatouk M, Ghedira K, et al
    Antitumoral, antioxidant, and antimelanogenesis potencies of Hawthorn, a potential natural agent in the treatment of melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    December 2015
  119. DE LIMA VAZQUEZ V, Vicente AL, Carloni A, Berardinelli G, et al
    Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  120. SEIFERT H, Fisher R, Martin-Liberal J, Edmonds K, et al
    Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  121. SHEPPARD HM, Feisst V, Chen J, Print C, et al
    AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  122. KOROKNAI V, Ecsedi S, Vizkeleti L, Kiss T, et al
    Genomic profiling of invasive melanoma cell lines by array comparative genomic hybridization.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  123. SCHREUER M, Meersseman G, van Den Herrewegen S, Jansen Y, et al
    Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  124. JACOBSOONE-ULRICH A, Jamme P, Alkeraye S, Dzwiniel V, et al
    Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  125. SONG H, Jing G, Wang L, Guo W, et al
    Periodic acid-Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  126. JANSEN YJ, Janssens P, Hoorens A, Schreuer MS, et al
    Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Melanoma Res. 2015;25:550-554.
    PubMed     Text format     Abstract available


  127. SEVIM DG, Kiratli H
    Serum adiponectin, insulin resistance, and uveal melanoma: clinicopathological correlations.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  128. OLSEN CM, Lane SW, Green AC
    Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    November 2015
  129. CAMPAGNE C, Reyes-Gomez E, Loiodice S, Gadin S, et al
    Haplosufficiency of PAX3 for melanoma development in Tyr: NRASQ61K; Cdkn2a-/- mice allows identification and sorting of melanoma cells using a Pax3GFP reporter allele.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    October 2015
  130. LI P, Liu J
    Diagnostic value of MRI and computed tomography in anorectal malignant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  131. EIBL-LINDNER K, Furweger C, Nentwich M, Foerster P, et al
    Robotic radiosurgery for the treatment of medium and large uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  132. BANERJEE M, Lao CD, Wancata LM, Muenz DG, et al
    Implications of age and conditional survival estimates for patients with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  133. IBRAHIM AM, Vargas CR, Koolen PG, Chuang DJ, et al
    Readability of online patient resources for melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  134. O'CONNELL EP, O'Leary DP, Fogarty K, Khan ZJ, et al
    Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  135. CINTOLO JA, Datta J, Xu S, Gupta M, et al
    Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    September 2015
  136. SHIMIZU A, Kaira K, Yasuda M, Asao T, et al
    Decreased expression of class III beta-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  137. RUBEGNI P, Feci L, Nami N, Burroni M, et al
    Computer-assisted melanoma diagnosis: a new integrated system.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  138. COUPS EJ, Manne SL, Stapleton JL, Tatum KL, et al
    Skin self-examination behaviors among individuals diagnosed with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  139. ROUX J, Pages C, Malouf D, Basset Seguin N, et al
    BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  140. OLIVER DE, Patel KR, Switchenko J, Parker D, et al
    Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  141. KELLER AK, Uter W, Pfahlberg AB, Radespiel-Troger M, et al
    Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  142. BERTOLLI E, Macedo MP, Pinto CA, Damascena AS, et al
    Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  143. TRIOZZI PL, Aldrich W, Crabb JW, Singh AD, et al
    Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  144. DUMMER R, Schadendorf D, Ascierto PA, Larkin J, et al
    Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  145. GONZALEZ-CAO M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, et al
    BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  146. THIERAUF J, Veit JA, Affolter A, Bergmann C, et al
    Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  147. LATIMER NR, Amonkar MM, Stapelkamp C, Sun P, et al
    Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    August 2015
  148. NAFFOUJE S, Naffouje R, Bhagwandin S, Salti GI, et al
    Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  149. FILITIS DC, Rauh J, Mahalingam M
    The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  150. SIISKONEN H, Poukka M, Bykachev A, Tyynela-Korhonen K, et al
    Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  151. GAMBICHLER T, Scheitz R, Hoxtermann S
    Serum anti-BPAG1 autoantibody level is not a useful biomarker for cutaneous melanoma.
    Melanoma Res. 2015.
    PubMed     Text format    


  152. SALGADO CM, Basu D, Nikiforova M, Hamilton RL, et al
    Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  153. RUINI C, Manfredini M, Pellacani G, Mandel VD, et al
    Confocal microscopy characterization of BRAFV600E mutated melanomas.
    Melanoma Res. 2015;25:367-371.
    PubMed     Text format     Abstract available


    July 2015
  154. MORENO-RAMIREZ D, Ojeda-Vila T, Rios-Martin JJ, Nieto-Garcia A, et al
    Association between tumor size and Breslow's thickness in malignant melanoma: a cross-sectional, multicenter study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  155. SHIMIZU A, Kaira K, Kato M, Yasuda M, et al
    Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  156. NOGUCHI S, Mori T, Nakagawa T, Itamoto K, et al
    DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  157. S AHMAD S, Qian W, Ellis S, Mason E, et al
    Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  158. BURGSTALLER-MUEHLBACHER S, Marko M, Muller C, Wendt J, et al
    Novel CDKN2A mutations in Austrian melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  159. JAKUB JW, Grotz TE, Jordan P, Hunter E, et al
    A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  160. DONINA S, Strele I, Proboka G, Auzins J, et al
    Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  161. SAROJINI S, Pecora A, Milinovikj N, Barbiere J, et al
    A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  162. LEJEUNE FJ
    The conquest of melanoma by immunotherapy.
    Melanoma Res. 2015.
    PubMed     Text format    


    June 2015
  163. DEROOSE JP, Grunhagen DJ, Eggermont AM, Verhoef C, et al
    Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  164. GOVERNA M, Caprarella E, Dalla Pozza E, Vigato E, et al
    Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  165. VAN BEEK JG, Koopmans AE, Vaarwater J, Verdijk RM, et al
    Metastatic disease in uveal melanoma: importance of a genetic profile?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  166. TOLK H, Satzger I, Mohr P, Zimmer L, et al
    Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  167. GORDON D, Gillgren P, Eloranta S, Olsson H, et al
    Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  168. JOSHUA AM, Monzon JG, Mihalcioiu C, Hogg D, et al
    A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  169. CHEVOLET I, Schreuer M, Speeckaert R, Neyns B, et al
    Systemic immune changes associated with adjuvant interferon-alpha2b-therapy in stage III melanoma patients: failure at the effector phase?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  170. TEJERA-VAQUERIZO A, Arias-Santiago S, Nagore E, Martin-Cuevas P, et al
    Defining the dermoscopic characteristics of fast-growing cutaneous melanomas.
    Melanoma Res. 2015;25:269-72.
    PubMed     Text format     Abstract available


  171. KAEHLER KC, Politz O, Henderson D, Ulbrich HF, et al
    Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
    Melanoma Res. 2015;25:225-31.
    PubMed     Text format     Abstract available


  172. YOUSAF N, Davidson M, Goode E, Thomas C, et al
    The cost of ipilimumab toxicity: a single-centre analysis.
    Melanoma Res. 2015;25:259-64.
    PubMed     Text format     Abstract available


    May 2015
  173. MINICHSDORFER C, Wasinger C, Sieczkowski E, Atil B, et al
    Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  174. NARDIN C, Puzenat E, Pretet JL, Algros MP, et al
    BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  175. ROLAND CL, Ross MI, Hall CS, Laubacher B, et al
    Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  176. CHALOPIN B, Florenceau L, Fradin D, Labarriere N, et al
    A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    April 2015
  177. SAKJI-DUPRE L, Le Rhun E, Templier C, Desmedt E, et al
    Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  178. BOHELAY G, Battistella M, Pages C, de Margerie-Mellon C, et al
    Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  179. FORTES C, Mastroeni S, Mannooranparampil TJ, Passarelli F, et al
    Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  180. DE FELICE KM, Gupta A, Rakshit S, Khanna S, et al
    Ipilimumab-induced colitis in patients with metastatic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  181. CHANG CL, Schabert VF, Munakata J, Donga P, et al
    Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    March 2015
  182. CARLOS G, Anforth R, Chou S, Clements A, et al
    A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  183. LINDNER T, Langner S, Falke K, Walter U, et al
    Anatomic and pathological characterization of choroidal melanoma using multimodal imaging: what is practical, what is needed?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  184. GANZETTI G, Rubini C, Campanati A, Zizzi A, et al
    IL-17, IL-23, and p73 expression in cutaneous melanoma: a pilot study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  185. CHOROMANSKA A, Kulbacka J, Rembialkowska N, Pilat J, et al
    Effects of electrophotodynamic therapy in vitro on human melanoma cells - melanotic (MeWo) and amelanotic (C32).
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  186. VAN ENGEN-VAN GRUNSVEN AC, Baar MP, Pfundt R, Rijntjes J, et al
    Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  187. FERRUCCI PF, Minchella I, Mosconi M, Gandini S, et al
    Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  188. VAN DEN HURK K, Balint B, Toomey S, O'Leary PC, et al
    High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  189. SEELEY AR, De Los Santos JF, Conry RM
    Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  190. JANGARD M, Zebary A, Ragnarsson-Olding B, Hansson J, et al
    TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    February 2015
  191. JIANG X, Asbach P, Willerding G, Dulce M, et al
    Dynamic contrast-enhanced MRI of ocular melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  192. DE ARAUJO ES, Kashiwabara AY, Achatz MI, Moredo LF, et al
    LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  193. HIEKEN TJ, Grotz TE, Comfere NI, Inselman JW, et al
    The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  194. JUNCO JJ, Mancha-Ramirez A, Malik G, Wei SJ, et al
    Ursolic acid and resveratrol synergize with chloroquine to reduce melanoma cell viability.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  195. O'LEARY DP, Byrnes KG, Power DG, Redmond HP, et al
    Surgical management of metastatic melanoma in the era of targeted systemic therapies.
    Melanoma Res. 2015;25:1-8.
    PubMed     Text format     Abstract available


  196. KALTOFT B, Hainau B, Lock-Andersen J
    Melanocytic tumour with unknown malignant potential--a Danish study of 67 patients.
    Melanoma Res. 2015;25:64-7.
    PubMed     Text format     Abstract available


    January 2015
  197. SEREMET T, Lienard D, Suppa M, Trepant AL, et al
    Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  198. YUE L, Huang ZM, Fong S, Leong S, et al
    Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  199. BONNELYKKE-BEHRNDTZ ML, Steiniche T, Damsgaard TE, Georgsen JB, et al
    MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  200. ZHOU Y, Zhang L, Fan J, Jia R, et al
    Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  201. OLIVER DE, Patel KR, Parker D, Delman KA, et al
    The emerging role of radiotherapy for desmoplastic melanoma and implications for future research.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    December 2014
  202. MA Y, Faller WJ, Sansom OJ, Brown ER, et al
    Fascin expression is increased in metastatic lesions but does not correlate with progression nor outcome in melanoma.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  203. VALPIONE S, Aliberti C, Parrozzani R, Bazzi M, et al
    A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  204. HENRY MN, Chen Y, McFadden CD, Simedrea FC, et al
    In-vivo longitudinal MRI study: an assessment of melanoma brain metastases in a clinically relevant mouse model.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


    November 2014
  205. DANLOS FX, Pages C, Roux J, Jebali M, et al
    Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  206. GUMMADI T, Zhang BY, Valpione S, Kim C, et al
    Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  207. UEN WC, Hsieh CH, Tseng TT, Jiang SS, et al
    Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  208. SHI H, Liu L, Liu LM, Geng J, et al
    Inhibition of tumor growth by beta-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  209. SCHREUER MS, Chevolet IL, Jansen YJ, Seremet TC, et al
    Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  210. MOSER JC, Pulido JS, Dronca RS, McWilliams RR, et al
    The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  211. ANFORTH RM, Carlos GR, Scolyer RA, Chou S, et al
    Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


  212. VULETIC AM, Jovanic IP, Jurisic VB, Milovanovic ZM, et al
    In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.
    Melanoma Res. 2014.
    PubMed     Text format     Abstract available


    October 2014
  213. RILEY PA
    Failure of fidelity of vertical transmission of epigenetic patterning as the basis of cancer.
    Melanoma Res. 2014;24:424-7.
    PubMed     Text format    


  214. ROBERT C, Thomas M, Mateus C
    MAP-kinase pathway up or down? Just look at the skin of your patients!
    Melanoma Res. 2014;24:421-3.
    PubMed     Text format    


  215. VOIT CA, van Akkooi AC, Eggermont AM, Tuttenberg A, et al
    Ultrasound diagnosis of an atypical axillary lesion.
    Melanoma Res. 2014;24:517-21.
    PubMed     Text format     Abstract available


  216. MCCORMACK CJ, Conyers RK, Scolyer RA, Kirkwood J, et al
    Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy.
    Melanoma Res. 2014;24:437-47.
    PubMed     Text format     Abstract available


  217. FORSCHNER A, Zips D, Schraml C, Rocken M, et al
    Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
    Melanoma Res. 2014;24:512-6.
    PubMed     Text format     Abstract available


    August 2014
  218. FUSI A, Hodgetts J, Dennis M, Lorigan P, et al
    Vemurafenib-induced nonautoimmune haemolytic anaemia.
    Melanoma Res. 2014;24:418-9.
    PubMed     Text format    


  219. VAN AKKOOI AC
    Sentinel node followed by completion lymph node dissection versus nodal observation: staging or therapeutic? Controversy continues despite final results of MSLT-1.
    Melanoma Res. 2014;24:291-4.
    PubMed     Text format    


    June 2014
  220. FILIMON A, Zurac SA, Milac AL, Sima LE, et al
    Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
    Melanoma Res. 2014;24:219-36.
    PubMed     Text format     Abstract available


    April 2014
  221. ROSS E, Robinson SE, Amato C, McMillan C, et al
    Therapeutic monoclonal antibodies in human breast milk: a case study.
    Melanoma Res. 2014;24:177-80.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: